The field of immuno-oncology has revolutionized cancer treatment by harnessing the power of the immune system to fight against cancer cells. Immuno-oncology Drugs, also known as immunotherapies, have emerged as a groundbreaking approach that aims to revive and strengthen the body's immune response against tumors.

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful pathogens, such as viruses and bacteria. However, cancer cells can evade detection and manipulation by the immune system, allowing them to grow and spread uncontrollably. Immuno-oncology drugs intervene in this process by boosting the immune system's ability to recognize and eliminate cancerous cells.

According to Coherent Market Insights, The Global Immuno-Oncology Drugs Market is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2022-2030).

One of the key types of Immuno-oncology Drugs is immune checkpoint inhibitors. These drugs target specific molecules, called checkpoints that act as "brakes" on the immune system's response to cancer cells. By blocking these checkpoints, immune checkpoint inhibitors unleash the immune system, allowing it to attack and destroy cancer cells more effectively.

Another class of immuno-oncology drugs includes monoclonal antibodies. These antibodies are designed to bind to specific proteins on cancer cells, marking them for destruction by the immune system. Additionally, monoclonal antibodies can stimulate immune responses or deliver toxic substances directly to cancer cells, further aiding in their elimination.

Cancer vaccines are also a promising avenue within immuno-oncology. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. These vaccines can be personalized to target specific tumor antigens, training the immune system to mount a targeted response against the cancer.

Another approach in immuno-oncology is adoptive cell therapy. This technique involves modifying a patient's own immune cells, such as T cells, to enhance their cancer-fighting abilities. These modified cells are then infused back into the patient, where they can seek out and destroy cancer cells.